Inhibiting the inflammasome with MCC950 counteracts muscle pyroptosis and improves Duchenne muscular dystrophy
BackgroundDuchenne muscular dystrophy (DMD) is the most common inherited human myopathy. Typically, the secondary process involving severe inflammation and necrosis exacerbate disease progression. Previously, we reported that the NLRP3 inflammasome complex plays a crucial role in this disorder. More...
Main Authors: | Nicolas Dubuisson, María A. Davis-López de Carrizosa, Romain Versele, Camille M. Selvais, Laurence Noel, P. Y. D. Van den Bergh, Sonia M. Brichard, Michel Abou-Samra |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-12-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1049076/full |
Similar Items
-
Intraperitoneal Injection of MCC950 Inhibits the Progression of Myopia in Form-Deprivation Myopic Mice
by: Zhengyu Chen, et al.
Published: (2023-10-01) -
MCC950 Ameliorates Diabetic Muscle Atrophy in Mice by Inhibition of Pyroptosis and Its Synergistic Effect with Aerobic Exercise
by: Xiaoyu Yan, et al.
Published: (2024-02-01) -
Adenine model of chronic renal failure in rats to determine whether MCC950, an NLRP3 inflammasome inhibitor, is a renopreventive
by: Mahmoud S. Sabra, et al.
Published: (2023-12-01) -
Histological Methods to Assess Skeletal Muscle Degeneration and Regeneration in Duchenne Muscular Dystrophy
by: Nicolas Dubuisson, et al.
Published: (2022-12-01) -
Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome in systemic lupus erythematosus
by: Xiaoxiao Wu, et al.
Published: (2024-03-01)